U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo

• Main Authors: Rafal Goraczniak, Brian A Wall, Mark A Behlke, Kim A Lennox, Eric S Ho, Nikolas H Zaphiros, Christopher Jakubowski, Neil R Patel, Steven Zhao, Carlo Magaway, Stacey A Subbie, Lumeng Jenny Yu, Stephanie LaCava, Kenneth R Reuhl, Suzie Chen, Samuel I Gunderson
• Format: Article
• Language: English
• Published: Elsevier 2013-01-01
• Series: Molecular Therapy: Nucleic Acids
• Subjects: cancer therapy; dendrimer; gene silencing; oligonucleotide therapeutic; tumor targeting
• Online Access: http://www.sciencedirect.com/science/article/pii/S2162253116301548

U1 Adaptor is a recently discovered oligonucleotide-based gene-silencing technology with a unique mechanism of action that targets nuclear pre-mRNA processing. U1 Adaptors have two distinct functional domains, both of which must be present on the same oligonucleotide to exert their gene-silencing function. Here, we present the first in vivo use of U1 Adaptors by targeting two different human genes implicated in melanomagenesis, B-cell lymphoma 2 (BCL2) and metabotropic glutamate receptor 1 (GRM1), in a human melanoma cell xenograft mouse model system. Using a newly developed dendrimer delivery system, anti-BCL2 U1 Adaptors were very potent and suppressed tumor growth at doses as low as 34 µg/kg with twice weekly intravenous (iv) administration. Anti-GRM1 U1 Adaptors suppressed tumor xenograft growth with similar potency. Mechanism of action was demonstrated by showing target gene suppression in tumors and by observing that negative control U1 Adaptors with just one functional domain show no tumor suppression activity. The anti-BCL2 and anti-GRM1 treatments were equally effective against cell lines harboring either wild-type or a mutant V600E B-RAF allele, the most common mutation in melanoma. Treatment of normal immune-competent mice (C57BL6) indicated no organ toxicity or immune stimulation. These proof-of-concept studies represent an in-depth (over 800 mice in ~108 treatment groups) validation that U1 Adaptors are a highly potent gene-silencing therapeutic and open the way for their further development to treat other human diseases.